<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016183</url>
  </required_header>
  <id_info>
    <org_study_id>220-011</org_study_id>
    <secondary_id>JapicCTI-132362</secondary_id>
    <nct_id>NCT02016183</nct_id>
  </id_info>
  <brief_title>Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)</brief_title>
  <official_title>ECARD Combination Tablets LD&amp;HD Special Drug Use Surveillance: Long-term Use (12 Months)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of long-term use of candesartan cilexetil /
      hydrochlorothiazide combination tablets (ECARD) Combination Tablets LD&amp;HD in hypertensive
      patients in the routine clinical setting
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a special drug use surveillance on long-term use of candesartan cilexetil /
      hydrochlorothiazide combination tablets (ECARD combination tablets) to evaluate in
      hypertensive patients in the routine clinical setting. Because the drug contains a diuretic
      (hydrochlorothiazide) , it is necessary to assess the safety,especially on serum uric acid.
      (the planned sample size is 3000).

      The usual adult dosage is 1 tablet (4 mg/6.25 mg or 8 mg/6.25 mg as a candesartan
      cilexetil/hydrochlorothiazide) administered orally once daily. This drug should not be used
      as a first-line drug for hypertension treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse drug reactions</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The frequency of adverse drug reactions by type, seriousness, time to onset. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with the study drug are defined as adverse drug reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in blood pressure</measure>
    <time_frame>From baseline to 12 months</time_frame>
    <description>Calculation of summary statistics for actual measured values and the change from baseline in systolic/diastolic blood pressure.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3157</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Candesartan cilexetil / hydrochlorothiazide</arm_group_label>
    <description>Candesartan cilexetil / hydrochlorothiazide combination tablets LD&amp;HD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan cilexetil / hydrochlorothiazide</intervention_name>
    <description>Candesartan cilexetil / hydrochlorothiazide combination tablets</description>
    <arm_group_label>Candesartan cilexetil / hydrochlorothiazide</arm_group_label>
    <other_name>ECARDÂ® Combination Tablets LD&amp;HD</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertensive patients

        Exclusion Criteria:

        (1) Patients with a history of hypersensitivity to ingredients of ECARD LD&amp;HD combination
        tablets, thiazides, or their analogues (e.g. sulphonamide derivatives such as
        chlortalidone) (2) Patients with anuria or patients under hemodialysis (3) Patients with
        acute renal failure (4) Patients with noticeably decreased Na and K levels in body fluids
        (5) Pregnant women or women planning to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2013</study_first_submitted>
  <study_first_submitted_qc>December 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <last_update_submitted>December 14, 2013</last_update_submitted>
  <last_update_submitted_qc>December 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 1, 2017</submitted>
    <returned>April 12, 2018</returned>
    <submitted>April 17, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

